Zhijian Xiao

20PUBLICATIONS
25CO-AUTHORS
Molecular targetsHaematological tumoursPredictive and prognostic markersSoftware quality, processes and metricsMedical biochemistry - proteins and peptides (incl. medical proteomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 29, 2026
Matching-Adjusted Indirect Comparison of Gecacitinib, Fedratinib, Pacritinib, and Momelotinib in Second-Line Myelofibrosis Therapy.

|Jun 22, 2026
Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study.

|Jun 18, 2026
Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

|Feb 27, 2026
Sex-Related Differences in Clinical Features, Inflammatory Cytokines, Mutation Topography, Outcomes, and Prognostic Models in Patients With Myeloproliferative Neoplasms.

Songyang Zhao, Xin Wang, Bing Li

|Nov 13, 2025
The dynamic alterations of DDX41 mutations in patients with myelodysplastic neoplasms treated with lenalidomide.

Junyun Liu, Yuwei Tang, Tiejun Qin

|Apr 08, 2025
Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes.

Zefei Bao, Bing Li, Tiejun Qin

Pageof 4

Frequent Collaborators

4 joint publications

Zefeng Xu

3 joint publications

Wenyu Cai

3 joint publications

Robert Peter Gale

2 joint publications

Gang Huang